Clene Inc. entered into Underwriting Agreement with Canaccord Genuity LLC valued at 1,000,000 shares of common stock at $7.00 per share for estimated net proceeds of $6.4 million (effective 2026-05-05).
“On May 5, 2026, Clene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), at an offering price of $7.00 per share.”
Material Agreements
Clene Inc. entered into Year 3 Subaward with New York University (NYU) valued at up to $8.0 million (effective 2026-03-13).
“On March 13, 2026, the Company entered into a subaward agreement for the third year of the NIH Grant with New York University (“NYU”), the prime awardee, for up to $8.0 million during the period from September 1, 2025 to August 31, 2026 (the “Year 3 Subaward”).”
Material Agreements
Clene Inc. entered into Securities Purchase Agreement with certain institutional investors, existing stockholders of the Company, and certain of the Company's directors valued at $6.50 per unit (effective 2026-01-08).
“On January 8, 2026, Clene Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, existing stockholders of the Company, and certain of the Company’s directors for the sale of (i) 928,333 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), (ii) warrants to purchase up to 1,114,000 shares of the Company’s common stock (the “Series A Warrants”) and (iii) warrants to purchase up to 2,599,333 shares of the Company’s common stock (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants”).”
Debt Financings
Clene Inc. incurred convertible notes of $1,500,000 aggregate principal amount with AE Capital Limited; A Global Chorus Foundation; Glenn and Shelina Way at 12% per annum, interest capitalized and added to principal balance maturing earlier of 18 months from closing or Change in Control.
“On August 13, 2025, the Company entered into a note purchase agreement (the “August 2025 Note Purchase Agreement”) by and among the Company and AE Capital Limited, A Global Chorus Foundation and Glenn and Shelina Way (together with AE Capital Limited and A Global Chorus Foundation, the “August 2025 Note Purchasers”), pursuant to which the Company agreed to sell, and the August 2025 Note Purchasers agreed to purchase, the Company’s senior secured convertible promissory notes (collectively, the “ August 2025 Notes”) in a principal amount totaling $1,500,000.”
Debt Financings
Clene Inc. amended convertible notes of original principal amounts unchanged (December 2024 Notes); monthly principal repayments of $1,000,000 per month deferre with Kensington Clene 2024, LLC; 4Life Research, LLC; La Scala Investments, LLC at interest capitalized and added to balance from August 1, 2025; at holder electio maturing maturity extended to earlier of February 13, 2027 or Change in Control.
“On August 13, 2025, Clene Inc. (the “Company”) entered into the first amendment (the “Amendment”) to the senior secured convertible promissory notes (collectively, the “December 2024 Notes”) which were issued by the Company on December 17, 2024 to Kensington Clene 2024, LLC (“Kensington”), 4Life Research, LLC (“4Life”) and La Scala Investments, LLC (“La Scala,” and collectively with Kensington and 4Life, the “December 2024 Note Purchasers”).”
Earnings Releases
Clene Inc. reported first quarter 2024 results: net income net loss of $11.1 million, EPS $0.09 per share.
“Clene reported a net loss of $11.1 million , or $0.09 per share, for the quarter ended March 31, 2024”
Material Agreements
Clene Inc. entered into Amended and Restated License Agreement with 4Life Research, LLC valued at exclusive, royalty bearing license; royalty rate 3% of incremental sales; term through 2033 (effective 2024-04-25).
“On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.”
Material Agreements
Clene Inc. entered into Amended and Restated Exclusive Supply Agreement with 4Life Research, LLC valued at cost plus 20% purchase price; Minimum Sales Commitments through 2033; royalty rate 3% of incremental (effective 2024-04-25).
“On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.